Coya Therapeutics (“Coya”) Announces the Appointment of Dr. Merit Cudkowicz, M.D., M.Sc., as Clinical Advisor to Support the Development of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
19 Julho 2023 - 8:00AM
Business Wire
- Dr. Merit Cudkowicz is the Director of the Sean M. Healey &
AMG Center for ALS, Chief of Neurology at Mass General, Director
and the Julieanne Dorn Professor of Neurology at Harvard Medical
School.
- Dr. Cudkowicz’s research and clinical activities are dedicated
to the study and treatment of people with ALS; she is one of the
founders and past Co-Chairs of the Northeast ALS Consortium
(NEALS), a group of over 134 clinical sites in the United States,
Canada, Europe and the Middle East dedicated to performing
collaborative clinical trials and research in ALS.
- Dr. Cudkowicz will support the development of Coya’s most
advanced clinical asset, COYA 302, a dual-mechanism investigational
biologic combination comprised of low dose Interleukin-2 (ld-IL2)
that is intended to enhance anti-inflammatory regulatory T cell
function with a fusion protein (CTLA4-Ig) that is intended to
suppress pro-inflammatory cell function.
- Coya previously reported positive clinical data for COYA 302
for the treatment of ALS in a four-patient, open-label
investigator-initiated trial illustrating that treatment with
LD-IL2 + CTLA4-Ig halted disease progression over 6 months, and
resulted in minimal decline over 12 months, in a cohort of patients
who were declining prior to study initiation at an average of -1.1
ALSFRS-R points per month.
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the
“Company”), a clinical-stage biotechnology company developing
biologics intended to enhance Treg function, today announced the
engagement of Merit Cudkowicz, MD, MSc as expert clinical advisor.
Dr. Cudkowicz is a world-renowned neurologist who has dedicated her
career to improving the life of patients with ALS and other serious
neurological conditions. Dr. Cudkowicz brings decades of experience
supporting the development of new therapies for ALS.
Dr. Cudkowicz is Principal Investigator of the Clinical
Coordination Center for the National Institute of Neurological
Disorders and Stroke’s Neurology Network of Excellence in Clinical
Trials (NeuroNEXT). Dr. Cudkowicz has launched the first platform
trial initiative in ALS, the HEALEY ALS Platform Trial, a program
that helps accelerate therapy development in ALS.
Dr. Cudkowicz received the American Academy of Neurology 2009
Sheila Essay ALS award, the 2017 Forbes Norris Award from the
International MND Alliance, the 2017 Pinnacle Award from the Boston
Chamber of Commerce and the 2019 Ray Adams American Neurological
Association Award. A dedicated educator, Dr. Cudkowicz mentors many
young neurologists in clinical investigation of ALS and related
neurodegenerative disorders. Dr. Cudkowicz completed her
undergraduate degree in chemical engineering at Massachusetts
Institute of Technology and obtained a medical degree in the Health
Science and Technology program of Harvard Medical School. She
served her internship at Beth Israel Hospital in New York and her
neurology residency and fellowship at Massachusetts General
Hospital. She also obtained a master’s degree in Clinical
Epidemiology from the Harvard School of Public Health.
Dr. Merit Cudkowicz commented: "I am happy to join Coya as a
clinical advisor as they move COYA 302 into a well powered and
designed clinical trial. COYA 302's dual mechanism of action in
enhancing Treg function and dampening other pro-inflammatory
pathways combined with their early clinical proof of concept data
provides strong rationale to move forward as a therapeutic strategy
in ALS."
"We are privileged to leverage Dr. Cudkowicz’s expertise in
supporting our clinical plans to rapidly advance COYA 302 in
patients with ALS,” added Fred Grossman, D.O., Coya’s President and
Chief Medical Officer.
About Coya Therapeutics, Inc.
Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq:
COYA) is a clinical-stage biotechnology company developing
proprietary treatments focused on the biology and potential
therapeutic advantages of regulatory T cells (“Tregs”) to target
systemic inflammation and neuroinflammation. Dysfunctional Tregs
underlie numerous conditions including neurodegenerative,
metabolic, and autoimmune diseases, and this cellular dysfunction
may lead to a sustained inflammation and oxidative stress resulting
in lack of homeostasis of the immune system. Coya’s investigational
product candidate pipeline leverages multiple therapeutic
modalities aimed at restoring the anti-inflammatory and
immunomodulatory functions of Tregs. Coya’s lead therapeutic
programs includes Treg-enhancing biologics (COYA 300 Series product
candidates) COYA 301 and COYA 302, which are intended to enhance
Treg function and expand Treg numbers. COYA 301 is a cytokine
biologic for subcutaneous administration intended to enhance Treg
function and expand Treg numbers in vivo, and COYA 302 is a
biologic combination for subcutaneous and/or intravenous
administration intended to enhance Treg function while depleting T
effector function and activated macrophages. These two mechanisms
may be additive or synergistic in suppressing inflammation. For
more information about Coya, please visit
www.coyatherapeutics.com
Forward-Looking Statements
This press release contains “forward-looking” statements that
are based on our management’s beliefs and assumptions and on
information currently available to management. Forward-looking
statements include all statements other than statements of
historical fact contained in this presentation, including
information concerning our current and future financial
performance, business plans and objectives, current and future
clinical and preclinical development activities, timing and success
of our ongoing and planned clinical trials and related data, the
timing of announcements, updates and results of our clinical trials
and related data, our ability to obtain and maintain regulatory
approval, the potential therapeutic benefits and economic value of
our product candidates, competitive position, industry environment
and potential market opportunities. The words “believe,” “may,”
“will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,”
and similar expressions are intended to identify forward-looking
statements.
Forward-looking statements are subject to known and unknown
risks, uncertainties, assumptions and other factors including, but
not limited to, those related to risks associated with the impact
of COVID-19; the success, cost and timing of our product candidate
development activities and ongoing and planned clinical trials; our
plans to develop and commercialize targeted therapeutics; the
progress of patient enrollment and dosing in our preclinical or
clinical trials; the ability of our product candidates to achieve
applicable endpoints in the clinical trials; the safety profile of
our product candidates; the potential for data from our clinical
trials to support a marketing application, as well as the timing of
these events; our ability to obtain funding for our operations;
development and commercialization of our product candidates; the
timing of and our ability to obtain and maintain regulatory
approvals; the rate and degree of market acceptance and clinical
utility of our product candidates; the size and growth potential of
the markets for our product candidates, and our ability to serve
those markets; our commercialization, marketing and manufacturing
capabilities and strategy; future agreements with third parties in
connection with the commercialization of our product candidates;
our expectations regarding our ability to obtain and maintain
intellectual property protection; our dependence on third party
manufacturers; the success of competing therapies or products that
are or may become available; our ability to attract and retain key
scientific or management personnel; our ability to identify
additional product candidates with significant commercial potential
consistent with our commercial objectives; ; and our estimates
regarding expenses, future revenue, capital requirements and needs
for additional financing.
We have based these forward-looking statements largely on our
current expectations and projections about future events and trends
that we believe may affect our financial condition, results of
operations, business strategy, short-term and long-term business
operations and objectives, and financial needs. Moreover, we
operate in a very competitive and rapidly changing environment, and
new risks may emerge from time to time. It is not possible for our
management to predict all risks, nor can we assess the impact of
all factors on our business or the extent to which any factor, or
combination of factors, may cause actual results to differ
materially from those contained in any forward-looking statements
we may make. In light of these risks, uncertainties and
assumptions, the forward-looking events and circumstances discussed
herein may not occur and actual results could differ materially and
adversely from those anticipated or implied in the forward-looking
statements. Although our management believes that the expectations
reflected in our forward-looking statements are reasonable, we
cannot guarantee that the future results, levels of activity,
performance or events and circumstances described in the
forward-looking statements will be achieved or occur. We undertake
no obligation to publicly update any forward-looking statements,
whether written or oral, that may be made from time to time,
whether as a result of new information, future developments or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230719552730/en/
Investor Contact David Snyder
david@coyatherapeutics.com
Hayden IR: James Carbonara (646)-755-7412
james@haydenir.com
Media Contact Anna Marie Imbordino
annamarie@quantum-corp.com 917-680-8765
Coya Therapeutics (NASDAQ:COYA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Coya Therapeutics (NASDAQ:COYA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024